Literature DB >> 30226586

Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells.

Melpomeni G Akrivou1, Vera P Demertzidou2, Nikoleta F Theodoroula1, Fani M Chatzopoulou3, Konstantinos A Kyritsis1, Nikolaos Grigoriadis4, Alexandros L Zografos2, Ioannis S Vizirianakis1.   

Abstract

The present study aimed to assess the pharmacological anticancer profile of three natural and five synthetic sesquiterpenes developed by total chemical synthesis. To this end, their properties at the cellular and molecular level were evaluated in a panel of normal and cancer cell lines. The results obtained by performing cytotoxicity assays and gene expression analysis by reverse transcription-quantitative polymerase chain reaction showed that: i) Among the sesquiterpene derivatives analyzed, VDS58 exhibited a notable anticancer profile within attached (U-87 MG and MCF-7) and suspension (K562 and MEL-745) cancer cell cultures; however, U-87 MG cells were able to recover their proliferation capacity rapidly after 48 h of exposure; ii) gene expression profiling of U-87 MG cells, in contrast to K562 cells, showed a transient induction of cyclin-dependent kinase inhibitor 1A (CDKN1) expression; iii) the expression levels of transforming growth factor β1 (TGFB1) increased after 12 h of exposure of U-87 MG cells to VDS58 and were maintained at this level throughout the treatment period; iv) in K562 cells exposed to VDS58, TGFB1 expression levels were upregulated for 48 h and decrease afterwards; and v) the re-addition of VDS58 in U-87 MG cultures pretreated with VDS58 resulted in a notable increase in the expression of caspases (CASP3 and CASP9), BCL2‑associated agonist of cell death (BAD), cyclin D1, CDK6, CDKN1, MYC proto-oncogene bHLH transcription factor (MYC), TGFB1 and tumor suppressor protein p53. This upregulation persisted only for 24 h for the majority of genes, as afterwards, only the expression of TGFB1 and MYC was maintained at high levels. Through bioinformatic pathway analysis of RNA-Seq data of parental U-87 MG and K562 cells, substantial variation was reported in the expression profiles of the genes involved in the regulation of the cell cycle. This was associated with the differential pharmacological profiles observed in the same cells exposed to VDS58. Overall, the data presented in this study provide novel insights into the molecular mechanisms of action of sesquiterpene derivatives by dysregulating the expression levels of genes associated with the cell cycle of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226586     DOI: 10.3892/ijo.2018.4550

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Synthesis, Biological Evaluation and Molecular Docking Studies of 5-Indolylmethylen-4-oxo-2-thioxothiazolidine Derivatives.

Authors:  Volodymyr Horishny; Athina Geronikaki; Victor Kartsev; Vasyl Matiychuk; Anthi Petrou; Pavel Pogodin; Vladimir Poroikov; Theodora A Papadopoulou; Ioannis S Vizirianakis; Marina Kostic; Marija Ivanov; Marina Sokovic
Journal:  Molecules       Date:  2022-02-05       Impact factor: 4.411

2.  Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2.

Authors:  Anthi Petrou; Panagiotis Zagaliotis; Nikoleta F Theodoroula; George A Mystridis; Ioannis S Vizirianakis; Thomas J Walsh; Athina Geronikaki
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411

3.  Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Authors:  Anthi Petrou; Phaedra Eleftheriou; Athina Geronikaki; Melpomeni G Akrivou; Ioannis Vizirianakis
Journal:  Molecules       Date:  2019-10-23       Impact factor: 4.411

4.  Thiazolidin-4-Ones as Potential Antimicrobial Agents: Experimental and In Silico Evaluation.

Authors:  Christophe Tratrat; Anthi Petrou; Athina Geronikaki; Marija Ivanov; Marina Kostić; Marina Soković; Ioannis S Vizirianakis; Nikoleta F Theodoroula; Michelyne Haroun
Journal:  Molecules       Date:  2022-03-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.